Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1
Deeksha Vishwamitra(Johnson & Johnson (United States)), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Cuc Davis(Janssen (United States)), Diana Cortés‐Selva(Johnson & Johnson (United States)), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Koen Van den Berge(Johnson & Johnson (United States)), Arnob Banerjee(Johnson & Johnson (United States)), Athena F. Zuppa(Children's Hospital of Philadelphia), Katherine Chastain(Johnson & Johnson (United States)), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Onsay Lau(Janssen (United States)), Jaymala Patel(Janssen (United States)), Lixia Pei(Janssen (United States)), Xin Miao(Johnson & Johnson (United States)), Rengasamy Boominathan(Janssen (United States)), Nizar J. Bahlis(University of Calgary), Caroline Hodin(Johnson & Johnson (United States)), Sheri Skerget(Johnson & Johnson (United States)), Niels W.C.J. Van de Donk(Amsterdam University Medical Centers), Yue Guo(Johnson & Johnson (United States)), Tatiana Perova(Janssen (United States)), Clarissa Uhlar(Johnson & Johnson (United States)), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes)
Cited by 0
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Trajectory-based differential expression analysis for single-cell sequencing data
|Nature Communications|2020|842